Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $380 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $380.
December 05, 2023 | 5:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Olivia Brayer reaffirmed an Overweight rating on Vertex Pharmaceuticals with a steady price target of $380.
The reiteration of an Overweight rating and the maintenance of a high price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on Vertex Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100